Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Information source: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Aripiprazole (Drug); Aripiprazole (Drug); Aripiprazole (Drug); Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute
episode of schizophrenia
Clinical Details
Official title: A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Change at endpoint in schizophrenia rating scale
Secondary outcome: Clinical Global Improvement scale at endpoint and time to response
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the
past three months
Locations and Contacts
Bristol-Meyers Squibb Call Center, Wallingford, Connecticut, United States
Additional Information
BMS Clinical Trials Disclosure For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm
Starting date: November 2003
Last updated: November 7, 2013
|